Press releases

Filter by year:

GeNeuro: financial information and business update for the second quarter 2022

Geneva, Switzerland, July 21, 2022, 5.45 pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 second quarter cash position and issued a business update.

GeNeuro Announces Approval of all Resolutions Proposed at 2022 Annual General Meeting

Geneva, Switzerland, June 2, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 31, 2022.

GeNeuro is granted authorization by the Swiss Health Authority (Swissmedic) to initiate a Phase II study evaluating temelimab in patients with severe neuropsychiatric post COVID syndromes

Geneva, Switzerland, May 11, 2022– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announces today it has received the authorization by the Swiss Health Authority (Swissmedic) to initiate a Phase II study evaluating temelimab in patients with severe neuropsychiatric post-COVID syndromes.

GeNeuro: financial information for the first quarter 2022

Geneva, Switzerland, April 15, 2022 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 first quarter cash position.

GeNeuro and FondaMental Foundation announce the first results of the collaboration for the development of diagnostic and therapeutic options for patients with post-COVID neuropsychiatric syndromes

Geneva, Switzerland, April 13, 2022 - 7:30 am CEST - GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), and the FondaMental Foundation, a scientific cooperation foundation serving patients with mental illness, presented at the Schizophrenia International Research Society (SIRS) congress from April 6 to 10 in Florence, Italy, the first data resulting from their collaboration launched in 2021, in the context of COVID.

GeNeuro Reports 2021 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 4, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), reports today its full-year results for the year ended December 31, 2021 and provided a corporate update.

ProTEct-MS Phase 2 trial confirms safety of higher doses of temelimab and synergistic potential to address neurodegeneration on top of anti-inflammatory treatment in multiple sclerosis

Geneva, Switzerland, March 21, 2022 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis, today announced that the top-line results of the ProTEct-MS study confirm the excellent safety profile and tolerability of higher doses of temelimab, up to 54mg/kg, used in combination with rituximab, a high-efficacy anti-CD20 drug, thus meeting the primary endpoint of the ProTEct-MS study.

GeNeuro announces the completion of its ProTEct-MS study and confirms the March timeline for top-line results, provides a Business Update and Cash Position as of December 31, 2021

Geneva, Switzerland, January 27, 2022 – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today that it has completed its ProTEct-MS clinical trial. The Company also reported its cash position as of December 31, 2021 and provided a business update.


Results 1-8 of 8